PMDA announcement on control of nitrosamine compounds in atomoxetine tablets
「アトモキセチン錠 ニトロソアミン化合物の管理について」を掲載しました
Published: 2026-09-10 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-09-11
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2026-09-10, the Pharmaceuticals and Medical Devices Agency (PMDA) announced that it had posted information on controlling nitrosamine compounds in atomoxetine tablets. The title does not specify control measures or implementation dates.
Business Impact
Manufacturers of atomoxetine tablets may be affected because the posted information concerns control of nitrosamine compounds in those tablets; the title alone does not establish specific requirements.
Recommended Action
Review of the official Japanese posting could clarify the control measures, intended recipients, and any applicable timelines.